← Back to Clinical Trials
Recruiting NCT04045587

NCT04045587 International Severe Asthma Registry: Canadian Cohort

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04045587
Status Recruiting
Phase
Sponsor University of British Columbia
Condition Severe Asthma
Study Type OBSERVATIONAL
Enrollment 714 participants
Start Date 2018-11-06
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 714 participants in total. It began in 2018-11-06 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The International Severe Asthma Registry is a global initiative looking to ensure that the care of people with severe asthma will continue to improve by collecting detailed information about the health and treatment of as many people with the disease as possible. The study will gather anonymized longitudinal real-life data for participants with severe asthma for five years. The purpose of the registry is to track the progress of participants and determine how well they are responding to treatment. Medical research using data from the registry will give the investigators a better understanding of severe asthma and help the investigators develop and improve the care and treatment for severe asthma participants. The Canadian cohort of the registry will collect information from Canadian participants with severe asthma across seven different sites.

Eligibility Criteria

Inclusion Criteria: * Participants 18 years or older * Participants receiving treatment according to GINA Step 5 or uncontrolled in GINA Step 4 (uncontrolled is defined as having severe asthma symptoms or frequent exacerbations) Exclusion Criteria: -Participants with mild to moderate asthma

Contact & Investigator

Central Contact

Shelley Abercromby

✉ Shelley.Abercromby@vch.ca

📞 (604) 875-4111

Principal Investigator

Celine Bergeron

PRINCIPAL INVESTIGATOR

University of British Columbia

Frequently Asked Questions

Who can join the NCT04045587 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Severe Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04045587 currently recruiting?

Yes, NCT04045587 is actively recruiting participants. Contact the research team at Shelley.Abercromby@vch.ca for enrollment information.

Where is the NCT04045587 trial being conducted?

This trial is being conducted at Edmonton, Canada, Edmonton, Canada, Vancouver, Canada, Vancouver, Canada and 8 additional locations.

Who is sponsoring the NCT04045587 clinical trial?

NCT04045587 is sponsored by University of British Columbia. The principal investigator is Celine Bergeron at University of British Columbia. The trial plans to enroll 714 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology